Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
Mar Mallo,
Heinz Tuechler,
Leonor Arenillas,
Sophie Raynaud,
Thomas Cluzeau,
Lee‐Yung Shih,
Chiang Tung‐Liang,
Christina Ganster,
Katayoon Shirneshan,
Detlef Haase,
Martí Mascaró,
Laura Palomo,
José Cervera,
Esperanza Such,
Nicola Trim,
Sally Jeffries,
Emma Ridgway,
Giovanni Marconi,
Giovanni Martinelli,
Francesc Solé
Affiliations
Mar Mallo
MDS Research Group Institut de Recerca Contra la Leucèmia Josep Carreras (IJC) ICO‐Hospital Germans Trias i Pujol Universitat Autònoma de Barcelona Badalona Spain
Heinz Tuechler
Boltzmann Institute for Leukaemia Research and Hematology Vienna Austria
Leonor Arenillas
Hematological Cytology Laboratory Pathology Department Hospital del Mar GRETNHE, IMIM (Hospital del Mar Research Institute) Barcelona Spain
Sophie Raynaud
Hematology Department Cote d'Azur University CHU of Nice Nice France
Thomas Cluzeau
Hematology Department Cote d'Azur University CHU of Nice Nice France
Lee‐Yung Shih
Division of Hematology Chang Gung Memorial Hospital‐Linkuo Chang Gung University Taoyuan City Taiwan
Chiang Tung‐Liang
Division of Hematology Chang Gung Memorial Hospital‐Linkuo Chang Gung University Taoyuan City Taiwan
Christina Ganster
Clinics of Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany
Katayoon Shirneshan
Clinics of Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany
Detlef Haase
Clinics of Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany
Martí Mascaró
Hematology Service Hospital Son Llàtzer Palma de Mallorca Spain
Laura Palomo
Experimental Hematology Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain
José Cervera
Hematology Service Hospital Universitario La Fe Valencia Spain
Esperanza Such
Hematology Service Hospital Universitario La Fe Valencia Spain
Nicola Trim
West Midlands Regional Genetics Laboratory Birmingham Women's Hospital Birmingham UK
Sally Jeffries
West Midlands Regional Genetics Laboratory Birmingham Women's Hospital Birmingham UK
Emma Ridgway
West Midlands Regional Genetics Laboratory Birmingham Women's Hospital Birmingham UK
Giovanni Marconi
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola Italy
Giovanni Martinelli
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola Italy
Francesc Solé
MDS Research Group Institut de Recerca Contra la Leucèmia Josep Carreras (IJC) ICO‐Hospital Germans Trias i Pujol Universitat Autònoma de Barcelona Badalona Spain
Abstract Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20–30% with the complementary application of genomic microarrays. We here present a multicenter collaborative study of 163 MDS cases with a normal karyotype (≥10 metaphases) at diagnosis. All cases were analyzed with the ThermoFisher® microarray (either SNP 6.0 or CytoScan HD) for the identification of both copy number alteration(CNA) and regions of homozygosity (ROH). Our series supports that 25 Mb cut‐off as having the most prognostic impact, even after adjustment by IPSS‐R. This study highlights the importance of microarrays in MDS patients, to detect CNAs and especially to detect acquired ROH which has demonstrated a high prognostic impact.